Q1 FY27 results: revenue dips 8%, PAT grows 13%
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.7 pts less than Nifty Microcap 250 and 7.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q1 FY27 (June 30, 2026) unaudited results. Net sales fell to Rs 693.22 lakhs from Rs 756.15 lakhs YoY, about 8.3 percent lower. Total income dropped from Rs 824.50 to Rs 730.10 lakhs. Despite the dip, net profit after tax rose to Rs 64.80 lakhs from Rs 57.28 lakhs, up around 13 percent. EPS improved to Rs 2.04 from Rs 1.80. The company operates in agri products. Auditors issued a clean, unmodified review report.
Revenue dipped 8% but PAT grew 13%, showing margin improvement. Clean audit review is reassuring.